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The latent viral reservoir is the major obstacle to achieving HIV remission and necessitates
life-long antiretroviral therapy (ART) for HIV-infected individuals. Studies in adults and chil-
dren have found that initiating ART soon after infection is associated with a reduction in the
size of the HIV-1 reservoir. Here we quantified cell-associated HIV-1 DNA in early-treated
but currently older HIV-infected children suppressed on ART.
Methods
The study participants comprised of a cohort of 146 early-treated children with HIV-1 RNA
<50 copies/ml enrolled as part of a clinical trial in Johannesburg, South Africa. A stored
buffy coat sample collected after a median 4.3 years on ART and where HIV-1 RNA was
<50 copies/ml was tested for cell-associated HIV-1 DNA levels. An in-house, semi-nested
real-time quantitative hydrolysis probe PCR assay to detect total HIV-1 subtype C proviral
DNA was used. Children were followed prospectively for up to 3 years after this measure-
ment to investigate subsequent HIV-1 RNA rebound/failure while remaining on ART. Age at
ART initiation, HIV-1 RNA decline prior to HIV-1 DNA measurement and other factors were
investigated.
Results
A gradient between age at ART initiation and later HIV-1 DNA levels was observed.
When ART was started <2 months of age, the lowest levels of cell-associated HIV-1 DNA
(median 1.4 log10copies/106 cells, interquartile range [IQR] 0.95–1.55) were observed
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compared to ART started at 2–4 months (median 1.68, IQR 1.26–1.97) or 5–14 months of
age (median1.98, IQR 1.69–2.25). A low CD4 T-cell count pre-treatment predicted higher
levels of HIV-1 DNA on later testing. The probability of HIV-1 RNA rebound >50 copies/ml
whilst on ART within 3 years after the DNA measurement was 2.07 (95% CI: 1.352–3.167)
times greater if the HIV-1 DNA level was above the median of 55 copies/106 cells.
Conclusions
Cell-associated HIV-1 DNA levels measured after more than 4 years on ART were lower the
younger the age of the child when ART was initiated. This marker of the size of the viral res-
ervoir also predicted subsequent viral rebound/treatment failure while ART was sustained.
The results provide additional evidence of the benefits of prompt diagnosis and early ART
initiation in newborns and infants.
Introduction
The latent viral reservoir is the major obstacle to achieving HIV remission and necessitates
life-long antiretroviral therapy (ART) for HIV-infected individuals. Studies have shown that
the size of the HIV-1 reservoir is reduced in adults identified soon after primary infection and
started rapidly on ART compared to those initiated on ART during chronic infection [1–3]. A
minority (5–15%) of adults treated during primary infection have been observed to control
viremia after ART is withdrawn [4–8]. Generally for adults who initiate ART during chronic
infection, almost all have immediate viral rebound when ART is withdrawn [4–8].
For perinatally-infected children, age at ART Initiation is roughly equivalent to time since
infection. Although the precise timing of perinatal infection cannot be determined, modelling
studies have suggested that infection early in pregnancy is rare and that most intrauterine
infections are likely to have occurred towards the end of pregnancy [9]. Transmission also
occurs intrapartum. Multiple studies have shown associations between younger age at start of
ART and smaller size of the viral reservoir [10–16]. However, these studies are mostly small,
have varying and often wide bounds around the time periods defined as early, and rarely
include comparisons with later treated children. Moreover, only one report has described viral
reservoir parameters from HIV-infected children living in sub-Saharan Africa where the HIV
epidemic predominates [17].
Studies of the viral reservoir in HIV-infected children have additional methodological chal-
lenges related to the limited blood volumes that can be collected from children. Moreover,
storage of viably-preserved PBMCs is costly and rare in studies undertaken in sub-Saharan
Africa. Quantitation of cell-associated HIV-1 DNA is one marker of the viral reservoir that
does not require large blood volumes or viably-preserved PBMCs. This marker is ideal when
high sensitivity is desired i.e. detection of low levels. Its limitation is that it does not distinguish
between viable and non-viable virus. Nevertheless, in a large study among early-treated adults,
quantitation of cell-associated HIV-1 DNA emerged as the strongest predictor of clinically-rel-
evant outcomes related to the size of the viral reservoir including time to viral rebound after
ART withdrawal [6].
We developed an in-house, semi-nested real-time PCR assay to quantitate cell-associated
HIV-1 DNA. The assay was designed with subtype C-specific primers and probes. Here we
describe relationships between this marker of viral reservoir size and other factors including
HIV DNA levels in early treated children
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age at ART initiation, pre-treatment characteristics, and subsequent viral rebound, in a cohort
of HIV-infected children treated as part of a clinical trial in Johannesburg, South Africa.
Methods
Study population
Stored samples were selected from children enrolled in an efavirenz-switch trial undertaken at
Rahima Moosa Mother and Child Hospital in Johannesburg, South Africa (NCT01146873)
[18, 19]. The trial randomized children who were suppressed (<50 HIV-1 RNA copies/ml) to
remain on a ritonavir-boosted lopinavir (LPV/r)-based regimen or to switch to an efavirenz-
based regimen. Other inclusion criteria included age older than 3 years and history of exposure
to nevirapine for prevention of mother-to-child transmission (PMTCT). All children had met
ART initiation criteria in place at the time. These included World Health Organization stage
III or IV disease, CD4+ T-cell percentage <25 if younger than 12 months or <20 if older than
12 months, or recurrent (> 2/year) or prolonged (> 4 weeks) hospitalization for HIV-related
complications. All children were initiated on a protease inhibitor-based regimen, mostly
LPV/r. Stavudine and lamivudine were the most widely used backbone drugs. The trial was
approved by the Institutional Review Boards of Columbia University and the University of the
Witwatersrand. The child’s guardian provided signed informed consent.
For this analysis, we selected the 24 week post-randomization sample from all children in
the trial who were 6 months of age or younger at the time of starting ART. One hundred and
fifty-two children met these criteria and samples were stored on 132. In addition, we selected
the same time point from a subset who had started ART 7–14 months of age. This subset con-
sisted of those who had been enrolled in the control arm (LPV/r) in a prior nevirapine-switch
trial [20] before enrolling in the efavirenz-switch trial. Twenty-nine children met these criteria
and samples were stored on 26.
This sample of 158 children was intended to over-represent those who initiated ART at a
young age. Plasma samples from the same time point were tested for anti-HIV-1 antibodies by
enzyme immunoassay (GenescreenTM HIV1/2 version 2; Bio-rad) as previously described
[21]. Consistent with manufacturer’s instructions, optical density (OD) readings below the
standard were defined as “negative,” above the standard and above one OD unit were defined
as “positive” and those with OD readings below one but above the standard were defined as
“low-positive”.
Clinical and laboratory data collected as part of the efavirenz-switch trial was used to
describe the population in terms of their pre-treatment characteristics, e.g. age at starting
ART, pre-treatment viral load, CD4+ T-cell count/percentage, etc., early response to ART
and characteristics at the time of HIV-1 DNA measurement. Children were followed until 48
weeks post-randomization as part of the trial. Thereafter they were enrolled in an observa-
tional study and followed with HIV RNA measurements at least every 6 months [19]. We
included in this analysis follow-up data collected through 36 months after the index HIV-1
DNA measurement.
Measurement of cell-associated HIV-1 DNA
We developed a semi-nested real-time quantitative hydrolysis probe (TaqMan) PCR assay (sn-
qPCR) to detect and quantify total HIV-1 subtype C proviral DNA based on methods previ-
ously described [22, 23]. The assay was designed to target the reverse transcriptase (RT) gene of
HIV-1 subtype C using all subtype C pol gene sequences available from the Los Alamos HIV-1
Database (http://www.hiv.lanl.gov).
HIV DNA levels in early treated children
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Briefly, the sn-qPCR is a two-step PCR with the first round of amplification carried out
using standard PCR on a conventional PCR machine and the following primers: forward
primer 5'-CAT TTC TTT GGA TGG GGT ATG A-3; reverse primer 5'-CCT GTT CTC
TGC CAA TTC TAA TTC TGC-3. The first round of PCR was allowed to proceed for 15
cycles only (i.e. halted in exponential phase). The total product of the first round PCR was sub-
sequently used in the second round of PCR, a real-time hydrolysis probe-based PCR using a
fluorescently-labelled TaqMan probe (5'-FAM-AGC TGG ACT GTC AAT GA-MGB-3'),
one primer identical to the forward primer used in the first round PCR and a second reverse
primer (reverse primer2: 5'-TTG CCC AGT TTA ATT TTC CCA CTA-3') designed to
bind ‘deeper’ within the amplicon. The second round PCR was carried out for the standard
cycle numbers used in real-time PCR (40 cycles). The first round PCR was set up in a 12¼l
final volume and subsequently diluted 1:8.3 to a 100 μl final volume in the second round
qPCR.
The numbers of HIV-1 proviral DNA copies were determined using the standard curve
method. To construct the standard curve, known copies of linearized p8MJ4 plasmid DNA,
cloned with a subtype C gag-pol gene, were serially-diluted and amplified in a background of
HIV-1-negative human gDNA (the same amount used in the experimental wells) and sub-
jected to the same cycling conditions described above. To minimize the possibility of cross-
contamination all reactions were set up using a 8-well PCR tube strip format with standard
curves being run concurrently on their own 8-well strip.
We compared serial plasmid dilutions that were amplified either by our in-house sn-qPCR
assay or a single-round qPCR using the same forward primer, reverse primer2 and probe (Fig
1). Although both the semi-nested as well as the single round assays can detect 1 single copy,
the cycle threshold (CT) where 10
5 copies of plasmid DNA is detected in the single round PCR
is equivalent to the CT region where a single copy is detected in the sn-qPCR (grey zones in Fig
1a and 1c). Thus a shift in CT from approximately 38 (single round PCR) to 25 (sn-qPCR) for
single copy amplification allows for considerably more confidence in the lower copy number
calls using sn-qPCR. Fig 1b and 1d show the corresponding standard curves and both have R2
values> 0.99 and PCR efficiencies > 99%. The assay was highly efficient at amplification of
plasmid DNA down to a single copy (10˚) as shown in Fig 1c and 1d.
Genomic DNA was extracted from 158 stored buffy coats (QIAamp DNA blood kit; Qia-
gen, Du¨sseldorf, Germany) selected for this analysis out of which 151 samples yielded suffi-
cient DNA for assaying (minimum cut-off of 400ng [6x104 leukocytes]). Where sufficient
DNA was available, samples were tested in triplicate (3 wells) with 875ng DNA/well (equiva-
lent to 3.98x105 leukocytes). In cases where there was insufficient DNA to perform three repli-
cates at that concentration, we tested all DNA available for that sample and if a positive result
was attained we calculated the DNA copies according to input gDNA (6/151 two replicates
and 3/151 one replicate). If we failed to get a result on the lower input DNA we intended to
exclude that sample from the analysis since we could not conclusively call it “undetected” due
to the lower input of DNA. However, none of the nine had to be excluded for this reason.
Although the assay was capable of detecting a copy number of 1, since we were only assaying
2625ng across three wells for most samples, a single copy detected in 2625ng equates to 3 cop-
ies/106cells, making this the limit of detection of the assay implemented in this study.
Statistical methods
HIV-1 DNA copies were expressed on the log10 scale with undetectable results recoded as 1
copy/106 cells = 0 log10 copies. The distributions of DNA log10copies were plotted using histo-
grams and medians and interquartile ranges (IQR) were calculated. Box-whisker plots were
HIV DNA levels in early treated children
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generated by key covariates. Analysis of variance (ANOVA) and pairwise t-tests were used to
test for differences between groups. Spearman Rank order correlations (rho) were calculated
to describe associations on the continuous scale. The non-parametric smoothing method
Locally Weighted Scatterplot Smoothing (LOWESS) was used to inspect for non-linear associ-
ations. Chi-squared tests were used to compare categorical variables between groups. To inves-
tigate whether there was an association between HIV-1 DNA levels and subsequent viral
rebound/treatment failure on ART, we divided the cohort above and below the median of 55
HIV-1 DNA copies/106 cells. Kaplan-Meier methods were used to examine time to viral
rebound/failure on ART >50,>400 and>1000 copies/ml over time up to 3 years after DNA
measurement in these two groups. P-values were calculated using log-rank tests. Multivariable
linear regression and Cox Proportional Hazards models were used to investigate independent
effects of the predictors. Analysis was conducted using SAS software (Cary, NC).
Results
Study participants
Of 151 children with HIV-1 DNA measured, 5 children had HIV-1 RNA >50 copies/ml at the
same visit and were excluded. The 146 HIV-infected children suppressed on ART at the time
of measurement had been initiated on ART between 6 weeks and 14 months of age (median
4.5 months, IQR: 3.0–5.8), were now a median of 4.6 years old (IQR: 3.9–5.2) and had been
treated for a median of 4.3 years (IQR 3.7–4.8) when cell-associated HIV-1 DNA was mea-
sured. Pre-treatment characteristics and profile at the time of measurement are shown in
Table 1. HIV-1 DNA could not be detected in three samples (2.1%) and the minimum
Fig 1. Comparison of reverse transcriptase-based single round qPCR (a and b) and sn-qPCR (c and d) assays designed to quantify subtype C
HIV-1 proviral DNA. Amplification curves (a and c) of ten-fold diluted plasmid (p8MJ4) DNA harboring subtype C HIV-1 gag-pol gene and
standard curves generated (b and d) from respective curves. Grey zone shows that the cycle threshold (CT) region where 10
5 plasmid DNA copies
are amplified in the single round qPCR (a) is equivalent to the CT region where a single copy (10˚) is amplified using the sn-qPCR assay. Eff = PCR
efficiency.
https://doi.org/10.1371/journal.pone.0195514.g001
HIV DNA levels in early treated children
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observed level of HIV-1 DNA was 3 copies/106 cells. The maximum was 1077, median 55, and
IQR 25 to 118 copies/106 cells.
Age at ART initiation
A significant but weak positive correlation was observed between HIV-1 DNA log10 copies/10
6
cells and age at ART start in months (rho = 0.327, p< .0001). A non-parametric smoothing of
the relationship (LOWESS) suggested that the relationship was linear through 5 months with-
out further association thereafter (Fig 2a). A box and whisker plot of HIV-1 DNA log10 copies/
106 cells and age at ART start in grouped month categories indicated that ART initiation at a
younger age was associated with lower levels of HIV-1 DNA (Fig 2b). ART started at5
months had the highest levels of HIV-1 DNA (median 1.98, IQR 1.69–2.25 log10 copies/10
6),
compared to ART started 2–4 months (median 1.68, IQR 1.26–1.97, p = 0.02) and started
under 2 months of age (median 1.4, IQR 0.95–1.55 p = 0.002). Examining the distribution of
HIV-1 DNA stratified into two groups above and below the median age of starting ART
revealed higher HIV-1 DNA levels in children who started ART4.5 months (median = 1.96,
IQR 1.52–2.25) compared to those starting ART <4.5 months of age (median 1.52,
Table 1. Characteristics of 146 treated HIV-infected children in Johannesburg, South Africa, at the time of mea-
surement of cell-associated HIV-1 DNA (current time) and at the time of antiretroviral therapy (ART) initiation.





Age at ART start in months 146 4.47 (2.96–5.76)
[0.79, 13.75]
Current age in years 146 4.58 (3.90–5.16)
[3.53, 7.54]





Current CD4 count in cells/mm3 140 1221 (977–1659)
[493, 3630]
Current CD4 percentage 140 35.4 (30.2–40.6)
[17.5, 56.9]
Pre-ART CD4 count in cell/mm3 137 1396 (755–1989)
[21, 3677]
Pre-ART CD4 percentage 139 23.4 (16.1–30.2)
[2.9, 80.0]





a Denominators are as shown and when less than 146 are explained by missing data
b Assays to quantitate HIV-1 RNA in clinical use at the time did not consistently quantitate>750,000 copies/ml
https://doi.org/10.1371/journal.pone.0195514.t001
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IQR 1.11–1.9, p = 0.0003) (Fig 2c). Two of the three children with undetectable HIV-1 DNA
had started ART below the median age of the group.
Other predictors
Duration of ART to the time of measurement was not associated with HIV-1 DNA levels
(r = 0.029; p = 0.73) (Fig 3a) nor was the closely related variable of child age (S1 Fig). There
was no association between HIV-1 DNA levels and child sex, current ART regimen, or current
CD4 T cell count or percentage (S2, S3, S4 and S5 Figs, Figs 3 and 4).
Lower pre-ART CD4+ T-cell count was significantly associated with higher HIV-1 DNA lev-
els (rho = -0.197, p = 0.02) (Fig 3c). Stratifying into pre-ART CD4+ T-cell count categories,
higher HIV-1 DNA levels were observed in those with a pre-ART CD4 count<500 cells/mm3
(median = 2.09, IQR 1.74–2.36) than in those with pre-ART CD4 counts 500–999 and>1000
cells/mm3 (median = 1.69, IQR 1.4–1.99, p = 0.09 and median = 1.68, IQR 1.3–2.02, p = 0.02,
respectively). Pre-ART CD4+ T cell percentage followed the same pattern but associations were
Fig 2. Associations between age at starting ART and cell-associated HIV-1 DNA levels after a median of 4.3 years of treatment among 146
HIV-infected children. a: Scatterplot of HIV-1 DNA log10 copies/10
6 cells (Y-axis) by age at ART start in months (x-axis). LOcally WEighted
Scatter-plot Smoother (LOWESS) and linear regression prediction lines are shown in blue and red, respectively; and the grey area shows the 95%
prediction elipse. b: Box and whisker plot of HIV-1 DNA log10 copies/10
6 cells by age at ART start groups; c: Histograms and estimated normal and
kernel distributions of HIV-1 DNA log10 copies/10
6 cells among those who started ART<4.5 and4.5 months of age.
https://doi.org/10.1371/journal.pone.0195514.g002
HIV DNA levels in early treated children
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weaker and non-significant. Higher pre-ART HIV-1 RNA levels showed a non-significant
trend towards being associated with higher HIV-1 DNA levels (rho = 0.122, p = 0.17) (Fig 3b).
To examine whether speed of initial HIV-1 RNA decline predicted later HIV-1 DNA levels,
we compared children who had achieved HIV-1 RNA <400 copies/ml by 6 months after ART
start (53.4%) to those who achieved suppression only later. There was no discernable differ-
ence in the HIV-1 DNA levels by this marker of speed of initial viral decline (S6 Fig).
The strong association between age at ART start was unchanged with the inclusion in a
multivariable model of pre-ART CD4+ T-cell count, pre-ART viral load, or duration of
treatment.
Association with HIV-1 antibody test
A non-reactive or low reactive HIV-1 antibody test was observed at the same time as the HIV-
1 DNA measurement in 23/74 (31.1%) children who started ART <4.5 months compared to
4/69 (5.8%) children who started4.5 months. We therefore restricted analysis of the associa-
tion between HIV-1 antibody and HIV-1 DNA levels to children who started ART <4.5
months. The median HIV-1 DNA levels were almost identical in those with non-reactive/low
Fig 3. Scatterplots showing associations between HIV-1 DNA log10 copies/10
6 cells and a: Time on ART in years; b: Pre-ART HIV-1 RNA copies/
ml and c: Pre-ART CD4 count in cells/mm3. LOcally WEighted Scatter-plot Smoother (LOWESS) and linear regression prediction lines shown in
blue and red, respectively.; grey area shows the 95% prediction elipse.
https://doi.org/10.1371/journal.pone.0195514.g003
HIV DNA levels in early treated children
PLOS ONE | https://doi.org/10.1371/journal.pone.0195514 April 12, 2018 8 / 14
vs. reactive HIV-1 antibody results (33 copies/106 cells) but the variance was larger in those
with non-reactive/low compared to reactive antibody results (0.515 vs. 0.235 log10 copies,
respectively, p = 0.02) (Fig 4).
Time to HIV-1 RNA rebound/failure on ART
Using Kaplan-Meier methods, time to HIV-1 RNA rebound >50 copies/ml, >400 copies/ml
and>1000 copies/ml up to 36 months after the index HIV-1 DNA measurement was signifi-
cantly faster for children with HIV-1 DNA>55 copies/106 cells compared to those with HIV-
1 DNA levels55 copies/106 cells (Table 2). When children were stratified by age at ART initi-
ation, stronger associations between HIV-1 DNA levels (each log10 increase) and subsequent
HIV-1 RNA rebound >50 copies/ml on ART (relative hazard (RH) = 2.908; 95% CI: 1.627–
5.200) were observed in the cohort who had started ART <4.5 months compared to the cohort
who started ART 4.5 months (RH = 1.308; 95% CI: 0.745–2.294) (Table 2). However, the
interaction term in the Cox model was not statistically significant. When considered on its
own, starting ART 4.5 months of age was associated with increased likelihood of HIV-1
RNA rebound >50 copies/ml on ART compared to starting ART earlier (RH = 1.55; 95% CI:
1.022–2.354). In a multivariable Cox model in the full cohort, cell-associated HIV-1 DNA
(each log10 increase) remained a strong predictor of subsequent rebound >50 copies/ml on
ART (RH = 2.146; 95% CI: 1.427–3.227) after adjusted for age at starting ART but age at start-
ing ART was no longer associated with subsequent viral rebound once HIV-1 DNA was in the
model. Inclusion of other covariates such as pre-treatment CD4+ T-cell count, pre-treatment
HIV-1 RNA and duration of treatment did not influence the results.
Discussion
We report here a gradient between younger age at ART initiation and lower levels of cell-
associated HIV-1 DNA measured in children suppressed on ART for just over 4 years. The
Fig 4. Histograms and estimated normal and kernel distributions of HIV-1 DNA log10 copies/10
6 cells by reactive
or non-reactive/low HIV-1 antibody results among 74 HIV-infected children who initiated ART< 4.5 months of
age.
https://doi.org/10.1371/journal.pone.0195514.g004
HIV DNA levels in early treated children
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gradient of benefit extended to starting ART up until around 6 months of age without a
discernable benefit thereafter. The Feibig classification system cannot be applied to perinatal
infection. However, in adult studies, treatment within 3–6 months of HIV-1 diagnosis, is
often included as a treatment category for acute infection [1–3]. Our results are consistent
with other studies in children but provide greater clarification of the effects of early ART in
narrower age intervals and in comparison to comparable control children initiating ART
only slightly later [10–17]. Our assay was developed specifically for subtype C virus and
targeted pol because of the highly-conserved regions within this gene. Nevertheless, the
primers do not overlap with any major NNRTI or NRTI mutations, and is therefore suitable
for treated patients.
We did not observe associations between cell-associated HIV-1 DNA and duration of ART.
This may be due to the cross-sectional design and only limited heterogeneity in cohort of dura-
tion of ART. In addition, since we measured HIV-1 DNA after more than 4 years of ART the
size of the viral reservoir may have stabilized. Generally, the most marked declines in HIV-1
DNA levels are within the first two years of treatment [13]. Associations between pre-treat-
ment characteristics including CD4 T cell count and HIV-1 RNA quantity were consistent
with expectations that pre-treatment disease severity would predict a larger persisting viral res-
ervoir. Higher concentrations of lymphocytes and different profiles of lymphocyte subsets in
neonates and infants compared to adults is one of the hypothesized reasons for potentially
favorable outcomes in early-treated infants [24, 25]. Surprisingly, CD4+ T-cell count was a
stronger predictor than CD4 T cell percentage which is the usually preferred parameter used
in clinical management of HIV-1-infected infants and young children. These results indicate
that, in this instance, pre-treatment CD4+ T-cell count is more informative than percentage.
The median concentrations of cell-associated HIV-1 DNA did not differ between those
with and without positive HIV-1 antibody results. We confined this analysis to children who









Hazard Ratio from Cox model comparing HIV-1 DNA >55
to 55 copies/106 cells
Probability of HIV-1 RNA >___ by ____
months (N with event)
>50 copies/ml
12 months 0.1020 (7) 0.1699 (10)
24 months 0.3681 (24) 0.4878 (28)
36 months 0.4629 (30) 0.7008 (40) 0.0006 2.07(95% CI: 1.352–3.167)
>400 copies/ml
12 months 0.0137 (1) 0.0837 (5)
24 months 0.1383 (9) 0.2274 (13)
36 months 0.1696 (11) 0.3177 (18) 0.0021 2.641 (95%CI: 1.389–5.022)
>1000 copies/ml
12 months 0.0137 (1) 0.0837 (5)
24 months 0.0915 (6) 0.1915 (11)
36 months 0.1072 (7) 0.2458 (14) 0.0187 2.526 (95%CI: 1.134–5.626)
a One child had no follow-up after HIV-1 DNA measurement and was excluded from this analysis.
https://doi.org/10.1371/journal.pone.0195514.t002
HIV DNA levels in early treated children
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had initiated ART under 4.5 months of age as we have previously reported that negative or low
antibody test results were fairly common in this age group but rarely observed in children who
started ART after 4 months of age as have others [21, 26]. We expected to observe that low/
negative antibody results would correlate with lower viral reservoirs but the data did not sup-
port this. We hypothesize that the third generation antibody assay that we used is too crude a
measure to discern how the viral reservoir might influence persisting HIV-1 antibodies. The
greater variability in the size of the viral reservoir in those children with negative/ low antibody
results is intriguing and should be further investigated longitudinally and with finer resolution
of antibody isotypes and antigen specificity.
A single cross-sectional measure of cell-associated HIV-1 DNA among children suppressed
on ART was a strong predictor of later HIV-1 RNA rebounds in plasma while children
remained on their ART regimen. Consistent adherence with lifelong ART is a challenge for all
HIV-infected individuals but has unique poignancy for growing children and their caregivers.
Fluctuating adherence over time is the most likely explanation for the viral rebounds observed.
Although believable measures of adherence are difficult to attain, we have no reason to expect
that adherence differed between children with larger vs. smaller viral reservoirs. Thus our
results suggest that children with smaller viral reservoirs may be somewhat protected from
treatment failure with fluctuating adherence. There are differing opinions about the value of
ART withdrawal in early-treated individuals once suppressed given that the rate of post-treat-
ment viral control for reasonable lengths of time is achieved in only a small minority. How-
ever, unplanned, unsupervised and usually unnoticed gaps in adherence are an almost
inevitable pattern in at least some patients. Our findings suggest that even through pessimism
about the capacity of early treatment on its own to achieve remission may be valid, a smaller
viral reservoir may provide some level of protection against treatment failure in the almost
inevitable event of periods of sub-optimal adherence.
Our study had several limitations. Viably-preserved PBMCs were not available for this
cohort. As a result HIV-1 DNA levels may be under-estimated compared to what may have
been observed if PBMCs and especially if isolated CD4+ PBMCs had been available. A single
marker was used to estimate the size of the viral reservoir and further studies characterizing
viral integration, viability, replication competence and other parameters will most certainly be
important. Despite the large size of the cohort in comparison to previous studies, numbers in
some sub-groups is small. Moreover, the relatively weak size of the association between HIV-1
DNA levels and age at starting ART and the wide variability indicate that age at treatment start
is only one factor among many influencing the size of the viral reservoir. Many parameters,
including the size of the HIV-1 DNA pool prior to starting ART a factor shown to be associ-
ated with later size of the reservoir [12, 27], were not available. HIV-1 DNA was measured at a
single time point several years after ART initiation. Longitudinal investigation of the viral res-
ervoir profile during the first two years after ART is initiated will be crucial to further our
understanding of how (and when) to intervene.
Conclusion
We provide strong evidence of an association between ART initiation within the first few
months of life and a reduced size of the viral reservoir several years later in children suppressed
on ART. We also demonstrate that a smaller viral reservoir once suppressed on ART is associ-
ated with lower likelihood of viral RNA rebounds over time among children on treatment.
The results provide additional evidence of the benefits of prompt diagnosis and early ART ini-
tiation in newborns and infants.
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Supporting information
S1 Fig. Scatterplot of HIV-1 DNA log10 copies/106 cells (Y-axis) by age of child when
tested.
(TIF)
S2 Fig. Histograms and estimated normal and kernel distributions of HIV-1 DNA log10
copies/106 cells by child sex: F = Female top panel M = Male lower panel.
(TIF)
S3 Fig. Histograms and estimated normal and kernel distributions of HIV-1 DNA log10
copies/106 cells by current treatment regimen: EFV = Efavirenz-based and LPV/
r = ritonavir-boosted lopinavir-based regimen.
(TIF)
S4 Fig. Scatterplot of HIV-1 DNA log10 copies/106 cells by current CD4 count.
(TIF)
S5 Fig. Scatterplot of HIV-1 DNA log10 copies/106 cells by current CD4 percentage.
(TIF)
S6 Fig. Histograms and estimated normal and kernel distributions of HIV-1 DNA log10
copies/106 cells by whether or not viral suppression (<400 copies/ml) was attained by 6
months after starting ART. No = suppression was not attained within 6 months of starting
ART. Yes = Suppression was attained at or before 6 months after starting ART.
(TIF)
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